Data at ECTRIMS will help back fenebrutinib as a potential addition to Roche’s arsenal of drugs, and help cement Ocrevus’s ...

The U.S. Food and Drug Administration (FDA) has approved the subcutaneous form of Keytruda for a new 'Under-the-Skin' Option for patients. The subcutaneous form of Keytruda showed to deliver the same ...

After a rocky regulatory pathway filled with delays and a previous rejection, the US Food and Drug Administration (FDA) has ...

The tennis star looked happy and slender in the skimpy baby blue lace-trimmed outfit that made the most of her slender legs.

Get going with our next company presenter at the BofA Healthcare Conference here in London. Pleased to be introducing Teva Pharmaceuticals and CEO, Richard Francis. My name is Jason Gerberry. I'm one ...

The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the ...

Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster ...

The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately to severely ...

The first immune checkpoint inhibitor that can be administered via subcutaneous injection in just 1 to 2 minutes has emerged.

Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s ...

The FDA has approved Keytruda Qlex, a faster, under-the-skin cancer treatment offering convenience and flexibility. Here's what we know.